J. Gale

发表

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

R. Laing, M. Parmar, M. Sydes, 2016, The Lancet.

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Matthew R. Sydes, Duncan B. McLaren, Eleftherios Sideris, 2018, European urology oncology.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array

J. R. Wilson, David M. Holden, P. W. Foster, 2016, British Journal of Cancer.

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

R. Laing, M. Parmar, M. Sydes, 2015, European urology.

Platinum Priority – Prostate Cancer

M. Sydes, D. Dearnaley, C. Parker, 2011 .

Analysis combining correlated glaucoma traits identifies five new risk loci for open-angle glaucoma

J. Haines, P. Mitchell, L. Pasquale, 2018, Scientific Reports.

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

M. Parmar, M. Sydes, D. Dearnaley, 2017, The New England journal of medicine.

Abiraterone acetate plus prednisolone improves survival in men with relapsed pros-

M. Parmar, M. Sydes, D. Dearnaley, 2021 .

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Warren C. Grant, M. Parmar, M. Sydes, 2021, The Lancet.

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

M. Sydes, D. Dearnaley, C. Parker, 2022, PLoS medicine.

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

M. Parmar, M. Sydes, D. Dearnaley, 2019 .

A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma

T. Powles, S. Sundar, S. Brock, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dexrazoxane efficacy for anthracycline extravasation: use in UK clinical practice

J. Gale, S. Muthuramalingam, J. Bradbury, 2013, International journal of clinical practice.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

M. Parmar, M. Sydes, D. Dearnaley, 2018, The Lancet.

Analysis combining correlated glaucoma traits identifies five new risk loci for open-angle glaucoma

J. Haines, P. Mitchell, L. Pasquale, 2018, Scientific Reports.

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

M. Sydes, D. Dearnaley, C. Parker, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

M. Parmar, M. Sydes, D. Dearnaley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA31_PRAdding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476)

M. Sydes, D. Dearnaley, J. Bono, 2017 .

611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)

Robin L. Jones, M. Parmar, M. Sydes, 2020 .

A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.

T. Powles, S. Sundar, S. Brock, 2022, Journal of Clinical Oncology.

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

M. Parmar, M. Sydes, D. Dearnaley, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

M. Parmar, M. Sydes, D. Dearnaley, 2023, The Lancet. Oncology.

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

M. Parmar, M. Sydes, D. Dearnaley, 2022, International journal of cancer.

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.

V. Goh, T. Powles, M. Highley, 2023, The Lancet. Oncology.

Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).

M. Parmar, M. Sydes, D. Dearnaley, 2017 .

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

M. Parmar, M. Sydes, D. Dearnaley, 2017, The New England journal of medicine.